Microbiome therapeutic shows promise in recurrent C. difficile
CP101, an investigational microbiome therapeutic, restored microbiome diversity and prompted a sustained clinical cure among patients with recurrent Clostridioides difficile infection, according to a presentation at this year’s ACG in Las Vegas.
“(The c. dif) therapies lead to significant microbiome disruptions which impairs colonization resistance,” Jessica R. Allegretti, MD, MPH, FACG, the director of fecal transplantatione at Brigham and Women’s Hospital and instructor of medicine at Harvard Medical School in Boston, said during her presentation at the ACG Annual Scientific Meeting. “Therefore, we desperately need new therapeutics to enhance microbiome recovery, measured by the increase in microbiome diversity, and enhance colonization resistance.”
Compared with placebo, patients dosed with CP101 demonstrated an improvement in sustained clinical cure (74.5% vs. 61.5%; P = .0488). An increase in microbiome diversity at week 1 correlated with sustained clinical cure through week 8.